Sep 2026· Movement Disorders· 0 citations· 43 references
Medicine
TL;DR
This study defined the serum metabolomic signature of MSA and highlighted novel biomarkers, pathological mechanisms, and therapeutic targets deserving further validation.
Abstract
Background
Multiple system atrophy (MSA) is an adult-onset, fatal, neurodegenerative disease lacking mechanistic understanding, early diagnosis, and specific treatments. Metabolomics has been widely used in neurodegenerative diseases for biomarker identification and pathophysiology exploration; however its application in MSA is extremely limited.
Objectives
To investigate the metabolomic landscape, core metabolic pathways, and novel biomarkers for MSA.
Methods
Untargeted metabolomics (ultra-high-performance liquid chromatography-Q-Exactive HF mass spectrometry [UHPLC-QE-MS]) was performed on serum samples from 85 MSA patients and 85 healthy controls (HCs). Candidate metabolites were validated via targeted metabolomics in an internal cohort (37 MSA, 36 HCs) and an external cohort (44 MSA, 44 Parkinson's disease [PD], 42 HCs). In vitro validation was performed using MO3.13 cells and SH-SY5Y cells overexpressing hSNCA.
Results
We identified 112 and 70 differential metabolites (DMs) in positive and negative modes, respectively. Pathway analysis revealed six significant pathways, including arginine and proline metabolism; pentose phosphate pathway; valine, leucine, and isoleucine biosynthesis; purine metabolism; arginine biosynthesis; and riboflavin metabolism. A riboflavin-xanthine panel effectively distinguished MSA from HCs (internal validation: [area under the curve [AUC] = 0.876), and this performance was confirmed in the external cohort (AUC = 0.943). Reduced xanthine levels in MSA patients compared with HCs and PD patients slightly enhanced the diagnostic power of neurofilament light chain for MSA-PD differentiation, boosting the AUC from 0.821 to 0.890. Both riboflavin and xanthine supplementation enhanced viability and reduced apoptosis in hSNCA-overexpressing MO3.13 cells, while only riboflavin exerted therapeutic effects in hSNCA-overexpressing SH-SY5Y cells.
An integrated multi-omics approach provides a robust framework for stage-specific PD monitoring and potential clinical deployment using multi-omics machine learning to identify biofluid-specific signatures and evaluated predictive performance.
A. Galal, Ahmed Moustafa, Mohamed Salama· npj Parkinson's Disease· 0 citations
Untargeted metabolomics enables identification of metabolically perturbed pathways during the acute phase of KD, and L-tyrosine, L-tryptophan, glutamine, histidine, histamine, and taurocholic acid may serve as candidate biomarkers for acute phase of KD.
Han-Qi Dai, Qian-Wen Wang, Yi Zhan· Frontiers in Medicine· 0 citations
Findings highlight coordinated dysregulation of amino acid and lipoprotein metabolism as hallmarks of established MS and identify a novel association of the omega-6/omega-3 ratio with inflammatory disease activity.
Rachel E. Rodin, B. Healy, Mariann Polgár-Turcsányi et al.· bioRxiv· 0 citations
Findings show that a non-invasive plasma multi-analyte panel can differentiate MSA from PD with clinically meaningful accuracy, and support prospective validation in larger cohorts.
This exploratory study integrates pilot-scale metabolomics with genetic analyses to identify candidate metabolic signals and inflammatory pathways linked to PD and indicated that SULT1A1 may partially mediate the association between 3-phenylpropionylglycine and PD.
Findings potentially advance the translational understanding of the gut–brain metabolic axis in neurodegeneration and support the exploratory clinical utility of microbiota-linked peripheral metabolic signatures as non-invasive auxiliary diagnostic tools for AD, awaiting external validation in larger, multi-center coho...
Jiao Chen, Xu-Hui Chen, Weiwei Yu et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.